Comparative analysis of isolated human bronchi contraction and biosynthesis of cysteinyl leukotrienes using a direct 5-lipoxygenase inhibitor

Biochemical Pharmacology

Volumn 54, Issue 4, 1997, Pages 437-442

  Bolla, Manlio ^a   Caruso, Paola ^b   Giossi, Massimo ^b   Folco, Giancarlo ^a   Civelli, Maurizio ^b   Sala, Angelo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Chiesi Farmaceutici ^*  (Italy)

Author keywords

5 lipoxygenase inhibition; Cysteinyl leukotrienes; Enzyme immunoassay; HPLC; Immunological challenge; Isolated human bronchi

Indexed keywords

CHF 1909; INDOMETACIN; LEUKOTRIENE B4; LEUKOTRIENE D4; LEUKOTRIENE E4; LIPOXYGENASE INHIBITOR; MEPYRAMINE; PEPTIDOLEUKOTRIENE; UNCLASSIFIED DRUG;

ARTICLE; BRONCHODILATATION; BRONCHOSPASM; CONTROLLED STUDY; DOSE RESPONSE; ENZYME IMMUNOASSAY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; SMOOTH MUSCLE CONTRACTION;

ARACHIDONATE 5-LIPOXYGENASE; BRONCHI; BRONCHOCONSTRICTION; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULIN E; LEUKOTRIENES; LIPOXYGENASE INHIBITORS;

EID: 0030981679     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00055-5     Document Type: Article

References (26)

1. Samuelsson B, Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 220: 568-575, 1983.
2. Drazen JM, Austen KF, Lewis RA, Clark DA, Goto G, Marfat A and Corey EJ, Comparative airway and vascular activities of leukotriene C-I and D in vivo and in vitro. Proc Natl Acad Sci USA 77: 4354-4358, 1980.
3. Ädelroth E, Morris MM, Hargreave FE and O'Byrne PM, Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med 315: 480-484, 1986.
4. Weiss JW, Drazen JM, Coles N, McFadden ER Jr, Weller PF, Corey EJ, Lewis RA and Austen KF, Bronchoconstrictor effects of leukotriene C in humans. Science 216: 196-198, 1982.
5. Dahlen S-E, Bjork J, Hedqvist P, Arfors K-E, Hammarström S, Lindgren J-A and Samuelsson B, Leukotriene promote plasma leakage and leukocyte adhesion in post-capillary venules: In vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 78: 3887-389, 1981.
6. Batt DG, 5-Lipoxygenase inhibitors and their anti-inflammatory activities. In: Progress in Medicinal Chemistry (Eds. Ellis GP and Luscombe DK), vol. 29, pp. 2-63. Elsevier Science Publishers B.V., Amsterdam, 1992.
7. von Sprecher A, Beck A, Gerspacher M, Sallmann A, Anderson GP, Subramanian N, Niederhauser U and Bray MA. Strategies in the design of peptidoleukotriene antagonists. J Lipid Med 6: 265-273, 1993.
8. Bjorck T, Harada Y, Dahlen B, Zetterström O, Johansson G, Rodriguez L, Hedqvist P and Dahlen S-E, Further evidence that leukotrienes are the major mediators of allergic constriction in human bronchi. In: Advances in Prosiaglandin, Thromboxane, & Leukotriene Research (Eds. Samuelsson B, et al.), vol. 21A, pp. 429-432. Raven Press, New York, 1990.
9. Sala A, Murphy RC and Voelkel N, Direct airway injury results in elevated levels of sulfidopeptide leukotrienes detectable in airway secretions, Prostaglandins 42: 1-7, 1991.
10. Pradelles P, Grassi J and Maclouf J, Enzyme immunoassay of eicosanoids using acetylcholinesterase as label: An alternative to radioimmunoassay. Anal Chem 57: 1170-1179, 1985.
11. Pradelles P, Antoine C, Lellouche J-P and Maclouf J, Enzymeimmunoassay for Leukotriene C4 and E4 using acetylcholinesterase. In; Methods in Enzymology-Arachidonate Related Lipid Mediators (Eds. Murphy RC and Fitzpatrick FA), vol. 87, pp. 82-89. Academic Press, New York, 1990.
12. De Lean A, Munson PJ and Rodbard D, Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235: E97-E102, 1978.
13. Dahlen S-E, Hedqvist P, Hammarström S and Samuelsson B, Leukotrienes are potent constrictors of human bronchi. Nature 288: 484-486, 1980.
14. Fleish JH, Rinkema LE, Haisch KD, Swanson-Bean D, Goodson T, Ho PPK and Marshall WS, LY171883 1-(2-hydroxy-3-propyl-4-(4-( 1H-tetrazol-5yl)butoxy)phenyl)-ethanone an orally active leukotriene D4 antagonist. J Pharmocol Exp Ther 233: 148-157, 1985.
15. Mong S, Wu HL, Miller J, Hall RF, Gleason JG and Crooke ST, SKF104353 a high affinity antagonist for human and guinea-pig lung LTD4 receptor blocked phosphatidylinositol metabolism and thromboxane synthesis induced by leukotriene D4. Mol Pharmacol 32: 223-229, 1987.
16. Sala A, Armetti L, Piva A and Folco GC, An improved assay for urinary LTE4. Prostaglandins 47: 281-292, 1994.
17. Holroyde MC, Altounyan REC, Cole M, Dixon M and Elliott EV, Bronchoconstriction produced in man by leukotrienes C and D. Lancet ii: 17-18, 1981.
18. Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JP and Lee TH, Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Resp Dis 143: 1025-1029, 1991.
19. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Gallery JC, Shapiro J, Cohn J, Rubin P, and Drazen JM, The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Resp Dis 148: 1447-1451, 1993.
20. MacGlashan DW, Schleimer RP, Peters SP, Schulman ES, Adams GK, Newball HH and Lichtenstein LM, Generation of leukotrienes by purified human lung mast cells. J Clin Invest 70: 747-751, 1982.
21. Salari H, Borgeat P, Fournier M, Hebert J and Pelletier G, Studies on the release of leukotrienes and histamine by human lung parenchymal and bronchial fragments upon immunologic and nonimmunologic stimulation. J Exp Med 162: 1904-1915, 1985.
22. Miadonna A, Tedeschi A, Brasca C, Folco G, Sala A and Murphy RC. Mediator release after endobronchial antigen challenge in patients with respiratory allergy. J Allergy Clin lmmunol 85: 906-913, 1990,
23. Wenzel SE, Larsen GL, Johnston K, Voelkel NF and Westcott JY. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Resp Dis 142: 112-119, 1990.
24. 4 levels during early and late asthmatic responses. J Allergy Clin lmmunol 86: 211-220, 1990.
25. 4 levels after allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis 144: 1411-1413, 1991.
26. Watanabe-Kohno S, Yasui K, Ohkawa E, Yamamura H, Horiba M, Inoue K and Ohata K, Effect of AS-35 on agonist-induced contractions and the resting tonus of airway smooth muscles and the in vitro release of chemical mediators from passively sensitized lung fragments from humans and guinea pigs. Jpn J Pharmacol 59: 227-233, 1992.